Magic™ Humanized PD-L1/CTLA-4 Dual Immune Checkpoint Knock-In Mice

  • Check with publisher
  • Published date: February 11, 2020
    • Shirley, New York, United States

Monoclonal antibodies (mAbs) are a rapidly growing class of human therapeutics representing an increasing number of drugs under development. Monoclonal antibodies have been used for treating cancer, autoimmune diseases, and infectious diseases in clinical practice. Antibody therapy directly targeted several immune checkpoints is demonstrating significant success in the past few years. Particularly, cancer therapy based on monoclonal antibodies against checkpoints of immune reaction is now regarded as a breakthrough method in oncological immunology. Nowadays, it is an urgent need to increase success rates of this immunotherapeutic approach and to extend it to more cancer types. Creative Biolabs, who always focuses on drug discovery and animal model, has successfully launched and established an exclusive Magic™ “humanized” animal model platform, which can provide the humanized PD-L1/CTLA-4 dual immune checkpoint knock-in mice to our clients all over the world. https://www.creative-biolabs.com/drug-discovery/therapeutics/magic-humanized-pd-l1-ctla-4-dual-immune-checkpoint-knock-in-mice.htm .

Jerry Carter
0 votes

Useful information

  • Avoid scams by acting locally or paying with PayPal
  • Never pay with Western Union, Moneygram or other anonymous payment services
  • Don't buy or sell outside of your country. Don't accept cashier cheques from outside your country
  • This site is never involved in any transaction, and does not handle payments, shipping, guarantee transactions, provide escrow services, or offer "buyer protection" or "seller certification"

Related listings

  • Magic™ Humanized PD-L1/TIM-3 Dual Immune Checkpoint Knock-In Mice

    Magic™ Humanized PD-L1/TIM-3 Dual Immune Checkpoint Knock-In Mice

    Biomedical Sciences Shirley (New York) February 11, 2020 Check with publisher

    The programmed cell death-ligand 1 (PD-L1), also known as B7-H1 or CD274, is commonly expressed on the surface of dendritic cells or macrophages. PD-L1 belongs to the family of immune checkpoint proteins and act as a co-inhibitory factor, which can s...

  • Magic™ Humanized PD-L1/TIGIT Dual Immune Checkpoint Knock-In Mice

    Magic™ Humanized PD-L1/TIGIT Dual Immune Checkpoint Knock-In Mice

    Biomedical Sciences Shirley (New York) February 11, 2020 Check with publisher

    Immune checkpoint-targeted therapy is producing unprecedented clinical results in various kind of cancer patients. Currently, researchers continue to identify an increasing number of immune checkpoints as novel targets for anti-tumor therapy. Co-enga...

  • Magic™ Humanized PD-L1/OX40 Dual Immune Checkpoint Knock-In Mice

    Magic™ Humanized PD-L1/OX40 Dual Immune Checkpoint Knock-In Mice

    Biomedical Sciences Shirley (New York) February 11, 2020 Check with publisher

    Therapeutic antibodies designed to block immune checkpoint receptors or activate immune-stimulatory receptors are a potent strategy to treat cancer and function by modulating a patient's own immune system. The combination immunotherapies that associa...